Traditional Big Pharma narrative of billion-dollar costs borne exclusively by producers for innovative drugs loses relevance. Many breakthrough therapies initiated in public institutions. These therapies developed using taxpayers' money. Narrative claimed costs ponoszonych solely by final producers. Development zapoczątkowany in public sectors undermines private-only innovation story.